Silvan Tuerkcan
Stock Analyst at Citizens
(3.88)
# 665
Out of 5,090 analysts
182
Total ratings
44.63%
Success rate
11.47%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $25 → $35 | $27.21 | +28.63% | 14 | Nov 26, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $8.31 | +20.34% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $8.18 | +156.72% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $9.77 | +115.05% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $5.06 | +58.10% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $13.07 | +68.39% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.87 | +221.72% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $20.55 | +65.45% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $35.95 | +25.17% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $44.40 | +12.63% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $58.85 | +46.13% | 16 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.93 | +153.16% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.85 | +55.84% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.58 | +96.51% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $8.31 | +1,344.91% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.44 | +598.15% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.29 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.03 | +290.24% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.00 | +162.66% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.38 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.83 | +24.22% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $155.27 | +80.33% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.20 | +76.47% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Nov 26, 2025
Maintains: Market Outperform
Price Target: $25 → $35
Current: $27.21
Upside: +28.63%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $8.31
Upside: +20.34%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $8.18
Upside: +156.72%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $9.77
Upside: +115.05%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $5.06
Upside: +58.10%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $13.07
Upside: +68.39%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.87
Upside: +221.72%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $20.55
Upside: +65.45%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $35.95
Upside: +25.17%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.40
Upside: +12.63%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $58.85
Upside: +46.13%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.93
Upside: +153.16%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.85
Upside: +55.84%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.58
Upside: +96.51%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $8.31
Upside: +1,344.91%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.44
Upside: +598.15%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.29
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.03
Upside: +290.24%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.00
Upside: +162.66%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.83
Upside: +24.22%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $155.27
Upside: +80.33%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.20
Upside: +76.47%